Reverse Due Diligence: How to Vet a Healthcare Buyer or Investor Before You Sign
Reverse due diligence is the work an owner does on a buyer or investor before signing an LOI or purchase agreement. It covers six areas: who controls the capital, what the public record shows, how the buyer has treated prior sellers, the background of the people who will run your company, conflicts among intermediaries, and whether the buyer can close on your timeline.
The reason is simple. In most PE and strategic deals, part of the price arrives after close as rollover equity or an earnout, and the buyer controls both. In the worked example below, 30 percent of a $20.0 million headline price depends on the buyer after the wire clears. Do the work before you grant exclusivity, while you still have other bidders.
Data as of November 20, 2026. Each figure names its source, population and date. Worked examples are hypothetical and use our arithmetic with stated assumptions.
The 12-Point Reverse Diligence Checklist
Run this before you sign an LOI. Once a buyer holds a no-shop clause, you have far less room to ask for documents.
| # | Check | What to request | Red flag |
|---|---|---|---|
| 1 | Source of capital | Equity commitment letter, debt commitment, fund documents | "We will raise it after LOI" |
| 2 | Fund vintage and hold period | Fund year, end of investment period, target exit window | Late-life fund buying with a short hold |
| 3 | Platform debt and cap table | Credit agreement summary, debt-to-EBITDA, preference stack above common | Rollover lands in common behind heavy debt and preferred |
| 4 | Acquisition list | Practices acquired in the last five years (anonymized at first) | Only a hand-picked reference list |
| 5 | Departed owners | Contacts for physicians or founders who left | No departed owner offered after you ask twice |
| 6 | Earnout record | Payout data on recent earnouts (template below) | "They always pay" with no data |
| 7 | Public records sweep | Your own searches (table below) | Exclusions, unsealed qui tam suits, prior platform bankruptcies |
| 8 | Background checks | Investigative reports on principals and board members | Fraud claims, regulatory bars, repeat seller litigation |
| 9 | Holdco insider screening | Written confirmation of the background checks the buyer ran on holdco directors and officers before offering you equity | No answer, or an answer that changes when pressed |
| 10 | Medicare ownership changes | Recent ownership changes the buyer reported to Medicare and how long billing took to normalize | Repeated enrollment or payment gaps |
| 11 | State notice plan | States that apply, who files, effect on closing date | Buyer unaware of the rules in your state |
| 12 | Intermediary conflicts | Written statement of who represents whom and every fee paid by either side | Undisclosed buyer-paid fees, or a disciplinary record |
Items 3, 6 and 9 carry the most weight when part of your price arrives after close. Pair this list with the LOI and term sheet red flags checklist.
Asking for Sensitive Data Without Killing the Deal
Some of these requests are commercially sensitive. A buyer may owe confidentiality to prior sellers, and a full earnout history reveals pricing. A refusal to hand over raw data is reasonable. A refusal to provide it in any form is a signal. Offer one of these formats and judge the buyer on whether it accepts one.
| Request | Sensitive because | Format a serious buyer can accept |
|---|---|---|
| Acquisition list | Seller identities, deals in negotiation | Anonymized list by specialty, state and close year. Names released for the references you shortlist |
| Earnout record | Pricing and seller confidentiality | Deal-by-deal table with names withheld, or aggregate figures certified by the CFO |
| Credit agreement | Lender terms | Summary of leverage, covenants and maturity, with the full document available to your advisers under NDA |
| Cap table and preferences | Sponsor economics | Waterfall showing where your rollover sits |
| Litigation history | Pending matters | Schedule of material suits, with sealed or settled matters described generally |
Put a mutual NDA in place before the first request. It removes the most common excuse and signals that you expect the buyer's records to stand up.
How to Read the Buyer's Answers
How the buyer answers tells you as much as what it says.
| Buyer response | What it tells you | Your move |
|---|---|---|
| Sends documents within a week, with unprompted extras | Organized platform that expects scrutiny | Proceed and verify |
| Sends documents only after LOI is signed | Wants exclusivity before disclosure | Hold the LOI until items 1 to 6 arrive in some form |
| Offers five hand-picked references, no list | Curated record | Ask for the anonymized list and pick your own |
| "Our earnouts always pay" with no data | No tracking, or bad results | Send the template below and set a date |
| Will not name the CFO who calculates the earnout | Earnout control sits with someone you cannot vet | Fix the accounting policy and dispute process in the agreement |
| Declines every format in the table above | Disclosure will not improve after signing | Move to the next bidder |
| Intermediary will not state in writing whom it represents and what it is paid | A conflict you cannot price | Hire your own adviser before going further |
Public Records to Pull Before the First Meeting
Every search below is free or close to it and takes an afternoon. Run each one on the sponsor, the platform, the platform's prior names and each principal who will hold a board seat.
| Record | Where to search | What it shows | What to look for |
|---|---|---|---|
| Form ADV | SEC Investment Adviser Public Disclosure (IAPD) | Registered and exempt reporting advisers, assets under management, private funds advised, disciplinary disclosures | Regulatory actions, a fund list that does not match the pitch |
| Form D | SEC EDGAR full-text search | Private offerings by funds and holdcos, amount sold, related persons, filing dates | Fund size far below the deal size, a "fund" that is a single-deal vehicle still raising |
| OIG exclusions | HHS-OIG List of Excluded Individuals/Entities (LEIE) | Persons and entities excluded from federal health care programs | Any match on a platform executive, medical director or affiliate |
| Federal exclusions | SAM.gov | Federal debarments and exclusions across agencies | Active records on the platform or principals |
| Federal court records | PACER | Civil suits, whistleblower fraud cases once unsealed, bankruptcy filings | Qui tam suits naming the platform, seller suits over earnouts |
| State courts | County and state court portals where the platform operates | Contract, employment and noncompete litigation | Repeat suits by former physician owners |
| Licensing boards | State medical, dental and nursing board lookups | License status and discipline | Board actions against the CMO or medical directors |
| Antitrust and AG actions | FTC cases and proceedings and state AG press releases | Complaints, consent orders, settlements | Orders that bind the sponsor's future deals or governance |
| Intermediary history | FINRA BrokerCheck | Registration and disciplinary history of brokers and firms | A disciplinary record. No record at all is not decisive on its own. The guide to choosing a healthcare investment banker covers who can be paid to sell a company, take questions about a specific adviser's fee to your own attorney |
A missing IAPD record does not settle the question either. Many single-family offices file nothing there. For them, Form D filings by their vehicles, state entity records and PACER carry more of the load.
FTC orders are public. A recent FTC consent order involving a healthcare private equity sponsor places continuing obligations on the sponsor, including on some of its future transactions. A sponsor under an order can still buy. You want to know about it because it can lengthen the path to the next exit, and the next exit is when your rollover gets paid.
Prior Platform Outcomes: The Bankruptcy Search
The acquisition list shows where a sponsor has been. Court records show how those platforms ended. For each healthcare platform the sponsor has controlled in the last ten years, run three searches:
- Bankruptcy court, by platform name and prior names. Look for reorganization or liquidation filings.
- Federal district court, by platform name with "qui tam" or "fraud." Unsealed cases show billing practices the platform defended under the sponsor's control.
- State court, by platform name with "earnout" or "breach." These suits come from sellers like you.
In a restructuring, secured lenders are paid first, then unsecured creditors, then preferred equity, then common. Rolled equity in a platform holdco usually sits in common. Ask the sponsor in writing: "Has any healthcare platform you controlled filed for bankruptcy, restructured its debt out of court or handed control to lenders? What did rollover holders receive?" Then compare the answer with the docket.
Four Buyer Types and the First Document to Request From Each
| Buyer type | Main risk to the seller | First document to request | Question that sorts good from bad |
|---|---|---|---|
| PE platform | Rollover and earnout depend on platform debt and exit | Credit agreement summary and cap table waterfall | "What did rollover holders receive at your last three exits?" |
| Family office | Decision authority and capital certainty | Entity chart and proof of funds at the investing vehicle | "Who signs, and who approves follow-on capital?" |
| Hospital or health system | Financial condition and later divestiture | Audited financials and strategic plan for your specialty | "Which service lines have you closed or sold in five years?" |
| Strategic or corporate | Integration terms and noncompete scope | Post-close org chart and employment terms | "Who will I report to, and what changes in year one?" |
PE platforms
Buyer interest follows spending. Per the CMS National Health Expenditure fact sheet, US spending on physician and clinical services grew 8.1 percent to $1,109.7 billion in 2024, and CMS projects it to grow 5.5 percent a year on average from 2025 through 2034. That steady growth is why outpatient practices keep drawing bidders, and why you will often have more than one buyer to vet.
In PE outpatient deals, the platform you join matters more than the sponsor's name. Of 148 private equity deals involving outpatient care providers announced in calendar 2025, as tracked by the Private Equity Stakeholder Project (PESP) and reported by Becker's ASC Review, 119 were add-on acquisitions. That is 80.4 percent by our arithmetic (119 ÷ 148), using PESP's own deal classification. In the same PESP 2025 count, dermatology led with 24 deals, eye care had 22 and oncology 9. When four in five deals are add-ons, your rollover usually lands on an existing platform's balance sheet. That platform's debt, management and exit plan set what the rollover is worth.
PE-owned practices also have shorter records. In the AMA Policy Research Perspective, Physician Practice Characteristics in 2024, 47.2 percent of physicians in hospital-owned practices said their practice was acquired before 2015. Among physicians in PE-owned practices, 17.1 percent said the same. Both figures are shares of AMA 2024 survey respondents within each ownership group. A platform with no completed exit gives you no evidence of how earlier rollover holders did, so ask for the sponsor's results at its other exits.
Bain & Company's Global Healthcare Private Equity Report 2026 reports that physician groups remain a major part of many PE portfolios even though deal volumes have fallen from their peak, and names nephrology, plastic surgery and behavioral health as specialties drawing interest. Owners in those specialties should expect several bidders and run the full checklist on each.
Hospitals and health systems
Hospital deal activity is rising, and many systems are selling assets as well as buying them. Kaufman Hall counted 56 hospital transactions announced through Q3 2026, against 46 in all of 2025, the lowest annual count since it began tracking in 2011 (Becker's Hospital Review on Kaufman Hall data). Of the 16 hospital and health system transactions announced in Q3 2026, divestitures made up nearly one-third and not-for-profits were most of the acquirers, per Kaufman Hall's Q3 2026 M&A Quarterly Activity Report press release (October 13, 2026). The same release reports a year-to-date hospital operating margin of 2.5 percent including allocations and nearly 43 percent of hospitals operating at a loss, both as of August 2026.
A system divesting today can divest your service line in three years. Ask a hospital buyer for:
- Audited financials for the last three years and the latest interim statements.
- Its own operating margin, set against the 2.5 percent Kaufman Hall figure.
- Every divestiture or service-line closure in the last five years.
- The strategic plan section covering your specialty.
- Any pending system-level merger, and who would control your contract afterward.
Family offices
Family offices raise three questions: who signs, whether capital is committed or raised deal by deal, and how long they intend to hold. Ask for the entity chart showing which vehicle will hold your stake, who controls it and who approves follow-on capital. Ask for proof of funds at that vehicle, not at the family's top entity.
Then test fit. Ask what board seats and consent rights the family expects, whether it has held a healthcare operating company through a full cycle and how it handled a portfolio company that missed plan. Call two operating companies it has backed, chosen by you from its list of holdings. If you are issuing equity to the family, ask early which investor documents its vehicle will provide so paperwork does not hold up closing. The family office healthcare investing guide covers structures in depth.
Worked Example: $6 Million of a $20 Million Price Rides on the Buyer
Hypothetical, our arithmetic. A specialty group with $2.0 million of EBITDA accepts an offer at 10.0x. Assume a cash-free, debt-free deal. All amounts are gross, before transaction fees, taxes and working capital adjustments, and all are shares of headline enterprise value.
| Component | Amount | Share of headline price |
|---|---|---|
| Headline enterprise value (10.0x × $2.0M) | $20.0M | 100% |
| Cash at close | $14.0M | 70% |
| Rollover equity in platform holdco, valued at the deal price | $4.0M | 20% |
| Earnout over two years, maximum | $2.0M | 10% |
| Value that depends on the buyer after close | $6.0M | 30% |
Part 1: Rollover against platform debt
Assumptions: the platform, including your practice, has $20.0M of EBITDA valued at 10.0x, or $200.0M of enterprise value. Debt stays constant to exit. All equity is one class of common, so the seller's stake equals $4.0M divided by platform equity at close, and the seller receives that share of exit equity.
Downside: platform EBITDA falls 15 percent to $17.0M and the exit multiple drops to 9.0x. Exit enterprise value is $153.0M.
| Debt at close | Debt ($M) | Equity at close ($M) | Seller's stake | Exit equity ($M) | Seller's value | Change on $4.0M |
|---|---|---|---|---|---|---|
| 5.0x | 100.0 | 100.0 | 4.0% | 53.0 | $2.12M | Down 47.0% |
| 6.0x | 120.0 | 80.0 | 5.0% | 33.0 | $1.65M | Down 58.8% |
| 7.0x | 140.0 | 60.0 | 6.7% | 13.0 | $0.87M | Down 78.3% |
Upside: platform EBITDA grows 30 percent to $26.0M and exits at 10.0x. Exit enterprise value is $260.0M.
| Debt at close | Exit equity ($M) | Seller's value | Change on $4.0M |
|---|---|---|---|
| 5.0x | 160.0 | $6.40M | Up 60.0% |
| 6.0x | 140.0 | $7.00M | Up 75.0% |
| 7.0x | 120.0 | $8.00M | Up 100.0% |
Enterprise value falls 23.5 percent in every downside row and rises 30.0 percent in every upside row. Debt magnifies both. Moving from 5.0x to 7.0x debt adds 31.3 points of downside loss and 40.0 points of upside gain.
Part 1b: Add a preferred layer
Real platforms often put sponsor preferred equity ahead of common. Assumptions: the 6.0x case, so $80.0M of equity at close. $30.0M of that is sponsor preferred, repaid in full before common receives anything, with no participation beyond its $30.0M. Accrued preferred returns are ignored, which flatters the seller. Common equity at close is $50.0M, and the seller's $4.0M is 8.0 percent of it. At exit, whatever remains after debt and the $30.0M preference goes to common pro rata.
| Case | Exit EV ($M) | Equity after debt ($M) | Preferred takes ($M) | Left for common ($M) | Seller's 8.0% of common | Change on $4.0M | Same case, no preferred |
|---|---|---|---|---|---|---|---|
| Downside | 153.0 | 33.0 | 30.0 | 3.0 | $3.0M × 8.0% = $0.24M | Down 94.0% | $1.65M |
| Upside | 260.0 | 140.0 | 30.0 | 110.0 | $110.0M × 8.0% = $8.80M | Up 120.0% | $7.00M |
The preferred layer turns a $1.65M downside result into $0.24M. An accruing preferred return would make it worse. This is why checklist item 3 asks for the full waterfall, not just the leverage multiple. Two platforms with identical debt can produce very different rollover outcomes.
Part 2: Who controls the earnout math
Assumptions: $1.0M of the earnout is payable in year one. Target EBITDA is $2.10M. Payout scales in a straight line from zero at 90 percent of target ($1.89M) to full at 100 percent ($2.10M), a band of $0.21M. The practice delivers $2.05M of EBITDA before any corporate charges.
| Scenario | EBITDA counted | Position in payout band | Year-one payout |
|---|---|---|---|
| No corporate allocation | $2.05M | ($2.05M − $1.89M) ÷ $0.21M = 76.2% | $0.76M |
| $100K platform overhead allocated to the practice | $1.95M | ($1.95M − $1.89M) ÷ $0.21M = 28.6% | $0.29M |
A $100,000 allocation decided by the buyer's CFO moves $0.48M of earnout, almost five times its size. Fix the accounting policy, allocation rules and dispute process in the purchase agreement before you sign, and put the person who runs the calculation on your background-check list. Model your own numbers in the rollover equity calculator.
The earnout record to request
Ask the buyer to complete this for each earnout in its last five years of deals, with names withheld if it prefers.
| Deal (anonymized) | Close year | Earnout size | Metric | Amount paid | Paid on time? | Disputed? | How resolved |
|---|---|---|---|---|---|---|---|
| Practice A | |||||||
| Practice B |
Check two or three rows against your reference calls. If the table says paid in full and the seller says otherwise, you have learned what you needed.
Background Checks on the People Who Will Run Your Company
Order investigative reports on individuals, not the fund: the operating partner who will chair your board, the platform CEO and the CFO who will calculate your earnout. Add any co-investor taking a board seat. Price depends on scope and the number of jurisdictions searched, and even a multi-state report on each person is small next to the $6.0 million at risk in the example above.
Rolled equity gives you a second screen. When you roll, you are buying an interest in the buyer's holdco, so the holdco's directors and officers deserve the same scrutiny as the platform team. Ask the buyer to confirm in writing what checks it ran on them and to share anything it disclosed to other investors. A buyer may route this through its counsel. A question that goes unanswered is a reason to pause.
Reference Calls: Four Owners, One in Person
You choose the references, not the buyer. Take the acquisition list from item 4 and pick at least four sellers, including one who has left the platform. Meet at least one in person or by video.
Ask each of them:
- Was the earnout paid in full and on time?
- Did the working capital true-up match what the LOI implied?
- What changed in compensation, staffing or scheduling in year one?
- How were disputes raised and resolved?
- Has the rollover been marked up or down since close?
- Would you sell to them again?
One unhappy seller is a data point. The same complaint from three is a pattern. Weigh the departed owner's call most heavily, since that person has no reason to protect the relationship. If references describe pay cuts for clinical staff after close, compare the new rates with regional wage data from the BLS Health Care and Social Assistance industry page to see whether retention will hold.
Regulatory Track Record
A buyer's regulatory history predicts your closing timeline. Ask these three questions and check the answers against the public record.
| Question for the buyer | The reason | Red flag |
|---|---|---|
| How many acquired practices did you move through Medicare ownership changes in the last two years, and how long until billing was normal? | Billing gaps after close hit cash flow and can depress earnout metrics | No data, or repeated multi-month gaps |
| Are you or your sponsor under any FTC or state AG order? | Orders can limit future acquisitions and governance | An order you found that the buyer did not mention |
| Which state notice filings have you made, and how did each affect the closing date? | Notice and review periods can push closing back by months | Buyer unaware of the rules in your state |
State healthcare transaction laws are spreading fast, and the Ropes & Gray HealthTrax tracker lists current laws by state. A buyer that has closed deals in your state should know the drill without being asked. Our guide to healthcare M&A process guide explains how these reviews can affect timing. Take questions about your own deal to your attorney.
Comparing Two $20 Million Offers on What Reaches You
Two offers with the same headline price can leave you with very different outcomes. Hypothetical, our arithmetic, using the figures from Parts 1 and 1b. Both bidders offer $20.0M: $14.0M cash at close, $4.0M rollover and a $2.0M earnout on identical terms, so the earnout is left out of the comparison. Bidder A runs its platform at 5.0x debt with one class of common. Bidder B runs at 6.0x debt with $30.0M of sponsor preferred ahead of common.
| Line | Bidder A (5.0x, no preferred) | Bidder B (6.0x, $30.0M preferred) |
|---|---|---|
| Cash at close | $14.0M | $14.0M |
| Rollover value, downside | $2.12M | $0.24M |
| Cash plus rollover, downside | $16.12M | $14.24M |
| Rollover value, upside | $6.40M | $8.80M |
| Cash plus rollover, upside | $20.40M | $22.80M |
| Gap between downside and upside | $4.28M | $8.56M |
Bidder B pays $2.40M more in the upside and $1.88M less in the downside. Its range is twice as wide. Diligence tells you which end of that range to believe.
| What diligence showed about Bidder B | Lean toward |
|---|---|
| Clean earnout record, references match it, and prior exits returned more than rollover holders put in | Bidder B, or ask B to match A's leverage |
| No completed exit at this platform and no data from the sponsor's other exits | Bidder A, or more cash at close from B |
| Waterfall withheld or preferred terms still open at LOI | Bidder A until the waterfall is in hand |
| Departed owners describe late or disputed earnouts | Bidder A, and test A's earnout record just as hard |
Before you put two offers side by side, collect the same four items from each bidder: leverage at close, the full waterfall including preferred terms, the completed earnout record and rollover results from the sponsor's last three exits. An offer you cannot fill in on every line is not yet comparable. If either bidder's model relies on an MSO or on ancillary and referral arrangements, read our guides on management services organizations and healthcare compliance due diligence guide, and take the questions they raise to your own attorney.
Turning Diligence Findings Into Deal Terms
Diligence pays off only when a finding changes the agreement. Use the worked example to put a dollar figure on each finding, then ask for the term that offsets it.
| Finding | Cost in the worked example | Term to ask for |
|---|---|---|
| Sponsor preferred ranks ahead of your rollover | Downside rollover value falls to $0.24M, against $1.65M with no preferred | Smaller rollover, more cash at close, or rollover in the same security the sponsor holds |
| Platform debt at 7.0x rather than 5.0x | Downside rollover value of $0.87M, against $2.12M | Smaller rollover, or a leverage figure disclosed and fixed before signing |
| Buyer's CFO decides overhead allocation | A $100K allocation cuts the year-one payout from $0.76M to $0.29M | Earnout EBITDA defined before corporate allocations, a fixed accounting policy and an independent accountant for disputes |
| No earnout record, or references describe late payment | Up to $2.0M, 10 percent of the price, rests on an untested promise | Move part of the earnout into cash at close, shorten the measurement period or require payment if the platform is sold first |
| No completed exit at this platform | No evidence of what earlier rollover holders received | Ask for results from the sponsor's other exits, and weight the offer toward cash |
What shifting rollover into cash does. Our arithmetic, using the 6.0x preferred case above. Move $2.0M of the $4.0M rollover into cash at close. Cash rises to $16.0M, or 80 percent of the price, and the value that depends on the buyer falls from $6.0M to $4.0M, or 20 percent. In the downside case the rollover loses 94.0 percent. On $4.0M that is a $3.76M loss. On $2.0M it is $1.88M.
The trade has a cost. In the upside case the rollover rises 120.0 percent, so the $2.0M you moved into cash would have grown to $4.40M. You give up $2.40M of potential gain to protect $1.88M of downside. Whether that trade is worth it depends on what diligence showed. A clean earnout record, a transparent waterfall and a sponsor with good prior exits make the upside more believable. Gaps in any of those make the cash more valuable.
A Reverse Diligence Timeline From First Meeting to Signing
See the healthcare M&A timeline chart.
| Stage | Reverse diligence step | Leaves this stage only when |
|---|---|---|
| First meeting | Public records sweep, FTC and AG orders, fund vintage, mutual NDA | Every exclusion or bankruptcy match is explained |
| Before LOI | Proof of capital, anonymized acquisition list, earnout record, bankruptcy search, background checks ordered | Items 1 to 6 are in hand in some form |
| Exclusivity | Four reference calls and one meeting, credit agreement summary and waterfall, holdco insider confirmation, state notice plan | References match the earnout table |
| Before signing | Intermediary disclosure, final background reports, Medicare ownership plan, earnout accounting fixed in the agreement | Every open item is resolved or priced |
Get a written statement from every intermediary naming the party it represents and every fee it receives from either side. The guide to choosing a healthcare investment banker explains the roles. A rollover or minority investor stays your partner until the next exit, so run the physician rollover equity checklist before you agree to a rolled stake.
Questions Owners Ask
Is it normal to run a background check on a buyer or investor?
Yes. Buyers check sellers, and sellers can check buyers. Start with free public records: Form ADV on the SEC's IAPD site, Form D filings on SEC EDGAR, the HHS-OIG exclusion list, SAM.gov and PACER. Then order investigative reports on the people who will sit on your board, run the platform and calculate your earnout. A report on the fund's name alone is not enough.
How many references should I call on a private equity buyer?
Speak with at least four sellers and meet at least one in person or by video. Pick them yourself from the buyer's acquisition list, which a buyer can share under NDA with practice names withheld until you shortlist. Include at least one owner who has left the platform. Ask whether earnouts paid in full, how disputes were resolved and whether they would sell to the same buyer again.
Which states require notice before a healthcare deal closes?
A growing number of states have healthcare transaction notice or review laws, and some of them reach private equity and MSO deals. A waiting period can move your closing date by months. Ask the buyer which state filings it has made before and how each one changed its closing timeline, and have your attorney confirm which rules apply to your deal.
What should I verify when a family office wants to invest in my company?
Confirm who makes the decision, where the capital sits and which entity will hold the stake. Ask whether capital is committed or raised deal by deal, how long the family intends to hold and what governance rights it expects. Get the entity chart before you send offering documents, and run the same public-records and background checks you would run on a PE sponsor.
Sources
- CMS, National Health Expenditure fact sheet (2024 data, 2025 through 2034 projections)
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- Becker's Hospital Review, Kaufman Hall Q3 2026 hospital transaction data
- Becker's ASC Review, PESP 2025 outpatient deal data
- Bain & Company, New Models of Value Creation for Physician Groups, Global Healthcare Private Equity Report 2026
- AMA Policy Research Perspective, Physician Practice Characteristics in 2024
- FTC, recent consent order involving a healthcare private equity sponsor
- Ropes & Gray, HealthTrax health care transaction laws tracker
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page
- SEC Investment Adviser Public Disclosure (Form ADV)
- SEC EDGAR full-text search (Form D)
- HHS-OIG List of Excluded Individuals/Entities
- FTC cases and proceedings
- FINRA BrokerCheck
- SAM.gov
- PACER, Public Access to Court Electronic Records